Daily BriefsMost Read

Most Read: Shanghai RAAS Blood Products C and more

In today’s briefing:

  • Haier Group to Buy $1.8B Stake in Shanghai RAAS from Grifols – A New Chapter Begins


Haier Group to Buy $1.8B Stake in Shanghai RAAS from Grifols – A New Chapter Begins

By Xinyao (Criss) Wang

  • Geopolitical risks have led to foreign companies planning to withdraw from China.It’s also difficult to allow foreign companies to control China’s core strategic assets.So, Grifols and RAAS’ “breakup” is inevitable.
  • This acquisition is an important milestone in the development of Haier’s big health industry. RAAS’s valuation also has room to rise further after being acquire by Haier due to synergies.
  • In the case of slowing growth in the home appliance market, this is a wise move for Haier.However, potential goodwill impairment in GDS is a risk for Haier/RAAS and investors.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars